Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and Research Institute, shared on LinkedIn:
“We presented the Preliminary Phase 2 data for vilastobart (XTX101), a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with advanced MSS CRC
– 40 patients with MSS CRC enrolled in ongoing Phase 2
– 18 response-evaluable patients with at least 1 scan reported
– Low incidence of immune colitis (5%)
– 3 of 11 patients without liver metastatic disease had partial response (27%)
To be continued …”
